This paper examines the critical shortage of available organs for transplant in the United States, where nearly 98,000 people await kidney transplants but fewer than 10,000 procedures occur annually. The author analyzes arguments both for and against financial compensation for organ donors, contrasting the current US ban on organ sales with practices in countries like China and Israel. Using consequentialist ethics as the analytical framework, the paper argues that compensating donors would increase organ availability, save lives, and respect individual autonomy over one's own body. The paper considers counterarguments regarding socioeconomic disparities, insurance implications, and long-term donor health risks, ultimately concluding that legalized compensation represents the most logical solution to the transplant shortage crisis.
In the United States, approximately 98,000 people are waiting for a new kidney, yet only 9,800 kidney transplants took place in 2013. This vast gap between supply and demand represents one of the most pressing challenges in modern healthcare. The kidney is the most sought-after organ for transplant because each human is born with two kidneys, and one is technically expendable while the person remains alive. Almost all other organs—such as the heart and liver—can only be donated after a person has died.
Kidneys possess a unique biological property: they can regrow like skin tissue. If a person loses up to 80 percent of kidney function, the remaining tissue can regenerate and eventually restore full kidney operation. This regenerative capacity makes the kidney an especially promising candidate for living donation programs. Despite this potential, the current legal framework in the United States prohibits the sale of organs for financial gain. Organs may only be transplanted if they are freely donated. In contrast, other countries like China and Israel permit organ sales; donors in these nations can receive up to $160,000, though after expenses for surgery and broker fees, the net payment typically ranges from $1,000 to $10,000.
Proponents of organ compensation argue that since organs are already sold on the black market, government regulation could ensure that transplant procedures are conducted safely and that donors are not placed at risk. Additionally, they contend that financial incentives would appeal to individuals facing financial hardship. A payment of $10,000 to a mother of three, for example, could significantly improve her family's quality of life. Because kidneys are renewable and one is technically expendable, supporters view compensation as a reasonable exchange for an organ that poses minimal long-term harm to the donor.
Furthermore, those favoring compensation note that most recipients of transplants belong to the upper middle class and higher income brackets—those who can afford the procedure. Making organs available through legal channels with financial incentives could help bridge the gap between wealthy recipients and economically vulnerable donors willing to sell.
Opponents of compensation raise several critical concerns. First, they argue that only lower and lower-middle-class individuals, driven by financial desperation, would donate organs. Evidence from blood and plasma donation programs supports this observation: the vast majority of compensated donors come from economically disadvantaged groups. Even with rigorous testing and matching protocols, many potential donors would be rejected and might attempt to sell organs on the black market anyway, undermining regulatory oversight.
Critics further contend that legalizing organ sales would not eliminate illegal trafficking—just as drug prohibition does not eliminate drug trafficking. Without government control over underground markets, the problem would persist alongside a legal market. Additionally, opponents highlight serious long-term risks: donors who sell one kidney and later develop kidney failure would be forced to purchase a replacement organ themselves, as they no longer have a "backup" kidney. Moreover, insurance costs could increase across the population if compensation payments must be subsidized or passed to consumers.
To evaluate this debate philosophically, consequentialism provides an appropriate framework. Under consequentialist ethics, the rightness of an action is determined by its outcomes. If a person chooses to sell an organ and accepts the consequences of that choice, that decision should be respected as a legitimate exercise of autonomy. The donor, as the rightful owner of organs within their own body, should have the choice to sell or retain them.
Consequentialist analysis also addresses the insurance argument: if a donor sells a kidney and later requires transplantation due to kidney failure, the responsibility lies with the donor's earlier choice. Insurance should not cover costs arising from self-imposed risk when the donor received financial compensation for that very risk. Under this framework, personal autonomy and accountability align logically.
"Author's reasoned position supporting financial incentives"
With so many people in the United States alone in need of organs and so few receiving them, finding ways to accumulate more available organs is essential. The most effective solution would be to compensate donors for their donations, which would increase donations exponentially. Thousands of lives would be saved, and over time, as more organs become available, the transplant waiting list could shrink to fewer than 10,000 people. Legalizing organ compensation represents the most logical and humane response to the transplant shortage crisis, provided that donors are fully informed of risks and held accountable for their choices. The ethical and practical case for regulated organ compensation is compelling.
You’re 88% through this paper. Sign up to read the remaining 1 section.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.